Simulations Plus, Inc.
1220 West Avenue J
Tel: 888-266-9294 US and Canada 661-723-7723<br>
301 articles with Simulations Plus, Inc.
Phase II Award of NIH Fast Track SBIR Grant for Drug-induced Kidney Injury Software, RENAsym™, Funds Development Over Next 20 Months
New models for in vitro systems lead to improved inputs for GastroPlus® simulations
Mr. O’Connor will host one-on-one meetings throughout the day at the conference which will be held at the Lotte New York Palace Hotel.
First quarter net revenues of $7.5 million reflecting 6.6% year over year growth
Conference Call to be on Wednesday, January 9, 2019, at 4:15 p.m. EST
Simulations Plus to Present at LD Micro 11th Annual Main Event Investor Conference on December 4, 2018
Simulations Plus, Inc. today announced that Shawn O’Connor, chief executive officer, and John Kneisel, chief financial officer, will present at the 11th Annual LD Micro Main Event investor conference at 9 a.m. PT on Tuesday, December 4, 2018, at the Luxe Sunset Boulevard Hotel in Los Angeles, California. The conference will be held December 4-6, 2018.
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of software for pharmaceutical discovery and development, today reported its financial results for its 2018 fiscal year (FY18) and fourth quarter (4Q18) ended August 31, 2018.
Simulations Plus, Inc. today announced that its board of directors has declared its next ongoing quarterly cash dividend of $0.06 per share of the Company’s common stock.
Incorporation of formulation characteristics into the GastroPlus™ mechanistic dermal absorption/PBPK model will inform regulatory decisions
Novel in silico Drug-induced Kidney Injury Model
Enhancements to mechanistic dermal absorption model in GastroPlus™ will target non-pharmaceutical markets
Record quarter as revenues grow 26.7%, 9MoFY18 net income up 63.8%
Simulations Plus, Inc. announced that it will report its third quarter financial results for fiscal year 2018, the period ended May 31, 2018, after the close of the financial markets on Tuesday, July 10, 2018.
Simulations Plus to Present at the 8th Annual LD Micro Invitational Investor Conference on June 5, 2018
Will present on Tuesday, June 5, 2018, at 9:30 a.m. Pacific Time and hold one-on-one meetings with institutional investors throughout the day.
Simulations Plus, Inc. (NASDAQ: SLP), the leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, and chemicals industries, today announced that it has released version 9.6 of its flagship PBPK modeling program, GastroPlus™.
Simulations Plus today announced the launch of version 2.0 of PKPlus, a major update to its software for analysis of preclinical and clinical trial data.
Cognigen today announced that it has released Version 2 of its KIWI Pharmacometric Communication and Collaboration Platform.
The cash dividend will be distributed on Friday, February 2, to shareholders of record as of Friday, January 26, 2018.
DILIsym Services Inc. announced that it has released Version 7A of its flagship QSP (quantitative systems pharmacology) modeling program, DILIsym.
Simulations Plus today reported financial results for its first quarter of fiscal year 2018, the period ended November 30, 2017 (1QFY18).